Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S418000, C514S227200, C544S253000
Reexamination Certificate
active
07087627
ABSTRACT:
Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of said compounds and treatment employing said materials.
REFERENCES:
patent: 9412165 (1994-06-01), None
patent: 9501972 (1995-01-01), None
patent: 9509621 (1995-04-01), None
patent: 9618617 (1996-06-01), None
patent: 9732585 (1997-01-01), None
patent: 9830537 (1998-07-01), None
Tozer et al., Cancer Res. (1999), 59(7), 1626-1634.
Stenger et al. (Eur. J. Pharmacol. 1995, 294, 703-12, see abstract only).
Narayanan et al (J. Biol. Chem. 1995, 270, 11103-10, see abstract only).
Blank M et al (Photochem Photobiol Sep. 2002;76: 335-40, abstract only with this Office Action).
Bonfoco et al (1995, Experimental Cell Research, vol. 218, pp. 189-200).
Ohsumi et al., J Med Chem. Jul. 30, 1998;41(16):3022-32.
Moilanen, E. et al. “Persistent Induction of Nitric Oxide . . . Acid” British J. of Cancer. vol. 77, No. 3, p. 426-433, (1988).
Chaplin, D.J. et al. “Modification of Tumor Blood Flow . . . Directions” Seminars in Radiation Oncology, vol. 8, No. 3, p. 151-163, (1998).
Effect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87. Glioblastoma: Clinical Cancer Research vol. 11 835-842, 2005: Phyllis R. Wachsberger, Randy Burd, nichol Marero, Constantine Daskalakis, Anderson Ryan, Peter McCue, Adam P. Dicker.
Annex A—Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues: Tozer, Prise, Wilson, Locke, Vojnovic, Stratford, Dennis, Chaplin: Cancer Research 59, 1626-1634, Apr. 1, 1999.
Annex B—Enhancement of Vascular Targeting by Inhibitors of Nitric Oxide Synthase: Davis, Tozer, Naylor, Thomson, Lewis, Hill: Int. J. Radiation Onocology Biol. Phys. vol. 54, No. 5 pp. 1532-1536, 2002.
Annex C—Effect of the tumor vascular damaging agent, ZD6126 on the radioresponse of U97 glioblastoma: Wachsberger, Burd, Marrrero, Daskalakis, Ryan, McCue, Dicker.
Angiogene Pharmaceuticals Ltd.
Ladas & Parry LLP
Yu Misook
LandOfFree
Combinations for the treatment of diseases involving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations for the treatment of diseases involving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for the treatment of diseases involving... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619721